Trial Profile

A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XAV-19 (Primary)
Indications COVID-19 pneumonia
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Acronyms POLYCOR

Most Recent Events

19 Mar 2022 Status changed from active, no longer recruiting to completed.
15 Jul 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
28 Jun 2021 Results (n=18) assessing the pharmacokinetics and safety of XAV-19, in COVID-19-related moderate pneumonia, published in the Antimicrobial Agents and Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com